# Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

> **NCT04743791** · PHASE4 · RECRUITING · sponsor: **Sally E. Wenzel MD** · enrollment: 30 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Dupilumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04743791
- **Lead sponsor:** Sally E. Wenzel MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-17
- **Primary completion:** 2026-07
- **Final completion:** 2026-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04743791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04743791, "Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04743791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*